Vertex Pharmaceutic (VRTX) Stock Price, Quote & News

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for peo...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 341 6100

Website: www.vrtx.com

Address:

50 Northern Avenue, Boston, United States

Iskill1 Aug. 25 at 12:24 PM

$QQQ Morning QQQ Watchlist 👀 $VRTX — bullish leader; D/W/M bullish with strong buying. $AMZN — bullish reversal; momentum improving, but structure still bearish. $ALNY — bearish laggard with Bear ABCD EXT near resistance. Conditional candidates — price must confirm.

0 · Reply

lextrading Aug. 25 at 3:10 AM

$VRTX One of few pharmas with a moat. They dominate the CF disease area.

0 · Reply

PaulMacfarland845 Aug. 22 at 3:43 PM

$VRTX $CSGP $BLK $MSTY $P Vertex benefits from pharmaceutical demand and pipeline expansion, CoStar benefits from commercial-real-estate data and marketplaces, BlackRock benefits from asset-management inflows, MSTY provides high-risk leveraged exposure tied to MicroStrategy, and P remains speculative. I'm watching prescription growth, real-estate activity, asset flows, Bitcoin prices, and liquidity.

0 · Reply

kamenrider888 Aug. 22 at 2:50 AM

$VRTX

0 · Reply

GorillaTrades Aug. 21 at 7:11 PM

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: LandBridge $LB +14.1%, Vertex Pharmaceuticals $VRTX +8.2%, and Nordson $NDSN +7.7%

0 · Reply

biotech Aug. 21 at 5:13 PM

$SGMO RBC suggesting $VRTX might need to rely on Nav1.7's re $SGMO

0 · Reply

biotech Aug. 21 at 5:07 PM

$SGMO NAV1.7 .... interest from multiple pot. #partners ... now bidders $VRTX $ABBV $LLY who else ???

0 · Reply

biotech Aug. 21 at 5:04 PM

$SGMO GUGGENHEIM : Non-Opioid Pain: $LLY 's Latest Deal Reinforces Sector-Wide Pharma Appetite for Next- Gen Pain Therapeutics ... $SGMO NAV1.7 epigenetic regulation more potential interested parties for september 2 auction on slide 2 it could be showdown $VRTX vs $LLY

0 · Reply

Stocktwits52wHighs Aug. 21 at 3:01 PM

$VRTX printed a new 52-week high today

0 · Reply

svertical1 Aug. 21 at 2:41 PM

$VRTX Nice retest for breakout holds. Very bullish!

0 · Reply

Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.

LLY MCK

Aug 3, 2026, 4:30 PM EDT - 21 days ago

Vertex Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 3, 2026, 4:30 PM EDT - 21 days ago

Vertex Pharmaceuticals Earnings release: Q2 2026

Aug 3, 2026, 4:30 PM EDT - 21 days ago

Vertex Pharmaceuticals Slides: Q2 2026

Aug 3, 2026, 4:30 PM EDT - 21 days ago

Vertex Pharmaceuticals Quarterly report: Q2 2026

Aug 3, 2026, 4:04 PM EDT - 21 days ago

Vertex raises annual revenue forecast on cystic fibrosis drugs strength

Aug 3, 2026, 4:01 PM EDT - 21 days ago

Vertex Reports Second Quarter 2026 Financial Results

Jul 8, 2026, 3:00 AM EDT - 6 weeks ago

How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks

CRNX

Jul 7, 2026, 4:00 PM EDT - 6 weeks ago

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Jul 7, 2026, 9:38 AM EDT - 6 weeks ago

Crinetics shares surge after Vertex agrees to $10B cash buyout

CRNX

Jul 7, 2026, 9:28 AM EDT - 6 weeks ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)

CRNX

Jul 7, 2026, 7:33 AM EDT - 7 weeks ago

This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal

CRNX

Jul 6, 2026, 5:02 PM EDT - 7 weeks ago

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion

CRNX

Jul 6, 2026, 4:30 PM EDT - 7 weeks ago

Vertex Pharmaceuticals Transcript: M&A announcement

Jul 6, 2026, 4:30 PM EDT - 7 weeks ago

Vertex Pharmaceuticals Press release: M&A announcement

Jul 6, 2026, 4:30 PM EDT - 7 weeks ago

Vertex Pharmaceuticals Slides: M&A announcement

Jul 6, 2026, 4:10 PM EDT - 7 weeks ago

Vertex to buy Crinetics in $10 billion deal

CRNX

Jul 6, 2026, 4:04 PM EDT - 7 weeks ago

Vertex to Acquire Crinetics Pharmaceuticals

CRNX

Jul 1, 2026, 7:58 PM EDT - 7 weeks ago

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

Jul 1, 2026, 6:45 PM EDT - 7 weeks ago

US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

Jun 11, 2026, 2:01 AM EDT - 2 months ago

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Jun 10, 2026, 11:20 AM EDT - 2 months ago

Vertex Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 5, 2026, 12:00 PM EDT - 2 months ago

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Jun 3, 2026, 4:00 PM EDT - 2 months ago

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

May 29, 2026, 9:00 AM EDT - 3 months ago

Vertex Pharmaceuticals Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 19, 2026, 2:35 PM EDT - 3 months ago

Vertex Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Vertex to Participate in Upcoming May Investor Conferences

May 6, 2026, 7:01 AM EDT - 3 months ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

May 4, 2026, 4:30 PM EDT - 4 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 months ago

Vertex Pharmaceuticals Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 months ago

Vertex Pharmaceuticals Slides: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 months ago

Vertex Pharmaceuticals Quarterly report: Q1 2026

May 4, 2026, 4:04 PM EDT - 4 months ago

Vertex tops profit estimates as sales of new cystic fibrosis drug surge

May 4, 2026, 4:01 PM EDT - 4 months ago

Vertex Reports First Quarter 2026 Financial Results

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 4:00 PM EDT - 5 months ago

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 1, 2026, 7:30 AM EDT - 5 months ago

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Mar 18, 2026, 2:23 PM EDT - 5 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mar 11, 2026, 11:30 AM EDT - 5 months ago

Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 1:22 PM EDT - 5 months ago

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Mar 10, 2026, 10:54 AM EDT - 5 months ago

Vertex passes key test In quest to treat kidney diseases

Mar 10, 2026, 10:00 AM EDT - 5 months ago

Vertex Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:13 PM EDT - 6 months ago

Vertex's kidney disease drug meets main goal in late-stage trial

Mar 9, 2026, 4:02 PM EDT - 6 months ago

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Mar 5, 2026, 4:00 PM EST - 6 months ago

Vertex to Participate in Upcoming March Investor Conferences

Mar 5, 2026, 10:00 AM EST - 6 months ago

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Mar 3, 2026, 9:10 AM EST - 6 months ago

Vertex Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 17, 2026, 4:00 PM EST - 6 months ago

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vertex Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vertex Pharmaceuticals Earnings release: Q4 2025

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vertex Pharmaceuticals Slides: Q4 2025

Feb 12, 2026, 4:06 PM EST - 6 months ago

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Feb 12, 2026, 4:01 PM EST - 6 months ago

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 2, 2026, 10:08 PM EST - 7 months ago

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Jan 22, 2026, 1:19 PM EST - 7 months ago

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

KMB XOM SPGI

Jan 20, 2026, 4:00 PM EST - 7 months ago

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Jan 12, 2026, 5:15 PM EST - 8 months ago

Vertex Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 8 months ago

Vertex Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 5:00 PM EST - 8 months ago

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Dec 22, 2025, 4:00 PM EST - 8 months ago

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Dec 6, 2025, 7:04 AM EST - 9 months ago

Vertex's gene therapy shows promise in younger children with blood disorders

Dec 6, 2025, 7:01 AM EST - 9 months ago

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Dec 3, 2025, 9:00 AM EST - 9 months ago

Vertex Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Nov 19, 2025, 4:00 PM EST - 9 months ago

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Nov 11, 2025, 10:15 AM EST - 10 months ago

Vertex Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Nov 8, 2025, 8:00 PM EST - 10 months ago

Vertex Pharmaceuticals Transcript: Study Update

Nov 8, 2025, 8:00 PM EST - 10 months ago

Vertex Pharmaceuticals Slides: Study Update

Nov 8, 2025, 5:15 PM EST - 10 months ago

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Nov 4, 2025, 1:22 PM EST - 10 months ago

Committee stocks on the move: Uber and Vertex Pharma

UBER

Nov 3, 2025, 4:30 PM EST - 10 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Vertex Pharmaceuticals Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Vertex Pharmaceuticals Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Vertex Pharmaceuticals Slides: Q3 2025

Nov 3, 2025, 4:20 PM EST - 10 months ago

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Nov 3, 2025, 4:02 PM EST - 10 months ago

Vertex Reports Third Quarter 2025 Financial Results

Oct 27, 2025, 4:00 PM EDT - 10 months ago

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Oct 23, 2025, 9:00 AM EDT - 10 months ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Iskill1 Aug. 25 at 12:24 PM

0 · Reply

lextrading Aug. 25 at 3:10 AM

$VRTX One of few pharmas with a moat. They dominate the CF disease area.

0 · Reply

PaulMacfarland845 Aug. 22 at 3:43 PM

0 · Reply

kamenrider888 Aug. 22 at 2:50 AM

$VRTX

0 · Reply

GorillaTrades Aug. 21 at 7:11 PM

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: LandBridge $LB +14.1%, Vertex Pharmaceuticals $VRTX +8.2%, and Nordson $NDSN +7.7%

0 · Reply

biotech Aug. 21 at 5:13 PM

$SGMO RBC suggesting $VRTX might need to rely on Nav1.7's re $SGMO

0 · Reply

biotech Aug. 21 at 5:07 PM

$SGMO NAV1.7 .... interest from multiple pot. #partners ... now bidders $VRTX $ABBV $LLY who else ???

0 · Reply

biotech Aug. 21 at 5:04 PM

0 · Reply

Stocktwits52wHighs Aug. 21 at 3:01 PM

$VRTX printed a new 52-week high today

0 · Reply

svertical1 Aug. 21 at 2:41 PM

$VRTX Nice retest for breakout holds. Very bullish!

0 · Reply

Jblack500 Aug. 21 at 2:28 PM

$HALO $VRTX new ath's

0 · Reply

thezenunderground Aug. 21 at 12:29 AM

$VRTX also, the weekly chart appears to be breaking out of a massive multi month bull flag

0 · Reply

thezenunderground Aug. 21 at 12:25 AM

$VRTX I went from not knowing about Journavx at all, to hearing about it all the time in the last couple weeks. I think this shit is gonna do monster numbers. So I bought the stock.

0 · Reply

PaulineBoudreaux971 Aug. 20 at 7:30 AM

$DHR $ISRG $VRTX $BMY $PLD Danaher benefits from life-sciences and diagnostics demand, Intuitive Surgical benefits from robotic-surgery adoption, Vertex benefits from pharmaceutical demand and pipeline progress, Bristol Myers Squibb remains driven by its drug portfolio, and Prologis benefits from logistics and warehouse demand. I'm watching biopharma spending, procedure volumes, clinical milestones, drug sales, and occupancy.

0 · Reply

Jblack500 Aug. 20 at 12:05 AM

$MRK $VRTX $GILD $HALO $ELAN ARWR BMY ANIP (May be looking at adding REGN with this breakout) https://www.fool.com/coverage/filings/2026/08/19/director-s-confidence-visible-as-elanco-leader-buys-10-000-shares/

0 · Reply

Jblack500 Aug. 19 at 9:35 PM

$VRTX breaking out

1 · Reply

MonkeyBananaGenius Aug. 19 at 9:06 PM

$VRTX

0 · Reply

BiotechButterflies Aug. 19 at 7:41 PM

$VRTX .. the squeeze....

0 · Reply

svertical1 Aug. 19 at 7:11 PM

$VRTX $600 INEVITABLE with Pove Approval! Povetacicept (pove) approval sooner than most think. Best-in-class or highly competitive candidate in several of these indications: •IgA Nephropathy (IgAN) •Lupus Nephritis (LN) and ANCA-Associated Vasculitis (AAV) •Generalized Myasthenia Gravis Most well rounded pipeline in Biotech. https://grok.com/share/c2hhcmQtMw_1a95c149-b4e0-4caf-918e-c19fab59a058

0 · Reply

judgeyoung2 Aug. 19 at 6:49 PM

So many mega bios breaking out at once today $MRK $AMGN $VRTX $LLY. ABBV?

1 · Reply

Arrow_Investments Aug. 19 at 5:27 PM

$VRTX 600

0 · Reply

Jblack500 Aug. 19 at 4:32 PM

$HALO $MRK $VRTX got ath's in these three. Great day for drug stocks

0 · Reply

Market Cap	139.10B
Revenue (ttm)	12.00B
Net Income (ttm)	3.95B
EPS (ttm)	N/A
PE Ratio	31.74
Forward PE	32.04
Profit Margin	32.94%
Debt to Equity Ratio	0.00

Volume	767,400
Avg Vol	1,604,730
Day's Range	N/A - N/A
Shares Out	253.81M
Stochastic %K	85%
Beta	0.30
Analysts	Strong Sell
Price Target	$560.65